the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Popular Thai herbal inhaler recalled after dangerous bacteria found

Thailand’s FDA has recalled the Hong Thai Herbal Inhaler Formula 2 after finding dangerous bacteria and fungi. The product isn’t approved by Malaysia’s NPRA.

A Thai herbal inhaler popular among Malaysians has been recalled after tests revealed it was contaminated with harmful microbes.

The Hong Thai Herbal Inhaler Formula 2, known for its compact size and refreshing scent, failed Thailand’s FDA safety tests after laboratory analysis detected bacteria and fungi contamination, including Clostridium spp. — a bacterium that can cause serious lung and respiratory infections.

According to Public Health Malaysia on Facebook, warn that inhaling contaminated products could allow these microbes to enter the respiratory tract.

It could potentially lead to coughing and breathing difficulties, lung infections (pneumonia), severe allergic reactions in asthma patients and blood infections among those with weakened immune systems.

The affected batch, numbered 000332, was produced on 9 December 2024 and set to expire on 8 December 2027.

While the inhaler is commonly brought home by travellers from Thailand, it is not registered with Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) — meaning it hasn’t undergone local safety evaluation.

Authorities advise the public to stop using the product immediately. Even herbal or “natural” remedies can pose risks if they haven’t been tested or approved by relevant health bodies.

“Don’t let a pleasant herbal scent put your health on the line.”

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings